OTEurope

Bausch & Lomb to buy eyeonics

Jan 25, 2008

Bausch & Lomb has entered into an agreement to purchase eyeonics, the maker of the Crystalens accommodating IOL.

Bausch & Lomb has entered into an agreement to purchase eyeonics, the maker of the Crystalens accommodating IOL.

Upon completion of the deal, Bausch & Lomb will absorb eyeonics' operations as part of its surgical business. Eyeonics generated approximately $34 million in revenue in 2007, a 100% increase over the prior year.

The acquisition is expected to complete within the first quarter of 2008.

Related Videos

Trukera Medical rebranding ushers in new era of expansion into cornea market

Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL

$Investigating better indications and outcomes in laser refractive surgery$

Avoiding errors when converting to DMEK

Related Content

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Related Content

Pearls for management of Pseudomonas scleritis

Pearls for management of Pseudomonas scleritis

Dr Zeba A. Syed emphasises the importance of performing surgery sooner rather than later for patients with Pseudomonas scleritis

An airport departure board shows a flight to Geneva is boarding. Image credit: ©WD Stockphotos – stock.adobe.com

Federal investment and regulatory benefits draw biotech firms to Switzerland

The country is home to 20% of biotechs headquartered in Europe.

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show

UK patients with vision loss confused by ‘disjointed’ benefits registration system

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Accessibility obstacles could prevent those with sight loss from receiving support and care.

Late spring heatwave poses vision risk to populations across Europe

Late spring heatwave poses vision risk to populations across Europe

What ophthalmologists want patients to know ahead of UK bank holiday.

Stating the facts about combination myopia management treatments

Stating the facts about combination myopia management treatments

Growing evidence supports dual therapy to slow progression.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.